Zoetis Inc. (NYSE:ZTS) Stake Lessened by Sanctuary Advisors LLC

Sanctuary Advisors LLC trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 14.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,271 shares of the company's stock after selling 17,976 shares during the period. Sanctuary Advisors LLC's holdings in Zoetis were worth $20,568,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services purchased a new stake in Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the 3rd quarter worth $33,000. Dunhill Financial LLC boosted its position in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP grew its stake in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company's stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS stock traded down $1.18 during mid-day trading on Friday, reaching $177.66. The company had a trading volume of 870,778 shares, compared to its average volume of 2,528,787. The stock's 50-day simple moving average is $180.82 and its two-hundred day simple moving average is $181.12. The stock has a market capitalization of $80.15 billion, a P/E ratio of 34.05, a P/E/G ratio of 2.89 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the business posted $1.36 EPS. Zoetis's revenue was up 11.6% on a year-over-year basis. Research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. This is a boost from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.13%. Zoetis's dividend payout ratio (DPR) is currently 32.33%.

Analysts Set New Price Targets

A number of research analysts recently commented on ZTS shares. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. UBS Group started coverage on shares of Zoetis in a research note on Monday. They issued a "neutral" rating and a $196.00 price target for the company. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective on the stock. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a research note on Wednesday, September 18th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $216.70.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.